Low-Volume Naltrexone Therapy
- Causes cell death of cancer cells and increases NK cells.
- Therapeutic Effect
- Treatment Process
- Treatment Cost
Treatment
What is Low-Dose Naltrexone Therapy?
Naltrexone is an internal medication that has been used as a remedy for drug addiction and alcoholism for over 30 years. However, recent clinical research on cancer treatment has shown that administration of a small amount of naltrexone is attracting attention as a therapeutic agent for controlling cancer cell growth / division / apoptosis.
Low-dose naltrexone therapy has furthermore attracted attention as being effective against diseases such as AIDS, multiple sclerosis and Parkinson’s.
Potentially Treatable Illnesses
Bladder cancer, malignant melanoma, breast cancer, multiple myeloma, carcinoid, neuroblastoma, colorectal cancer, ovarian cancer, uterine cancer, glioblastoma, pancreatic cancer, liver cancer, prostate cancer, lung cancer (NSCLC), renal cell cancer, lymphocytic leukemia (chronic), Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and throat cancer.
Therapeutic Effect
Effect of Low-Dose Naltrexone (LDN) on 450 Cancer Patients
Investigation of Low-Dose Naltrexone (LDN) Cancer Cases by the National Cancer Institute (NCI)
In June 2002, a cancer specialist and oncologist at the National Cancer Institute was invited by Dr Bihari. Some 30 medical case files of cancer patients of the Bihari Clinic were reviewed. Approximately half were selected as apparently having responded to low-dose naltrexone without any problem.
In March 2004, Dr Bihari reported that 450 patients who did not respond to standard treatment were treated with low-dose naltrexone (LDN) therapy and were effective at over 60%.
Mechanism of Tumor Growth Suppression by Low-Dose Naltrexone
- It induces elevation of methoenekephalin (endorphin produced in large amounts in the adrenal medulla) and beta-endorphin in the bloodstream.
- By inducing an increase in the number and density of opioid receptors on the tumor cell membrane, it increases apoptosis (cell death) of the cancer cells by increasing the reactivity of the receptor to the growth inhibitory effect from of existing endorphin concentration.
- Increases the number and activity of natural killer (NK) cells and the number of lymphocyte-activated CD8 cells in response to increased endorphin concentration.
- Since September 2006, the University of Minnesota Eye Sonic Gun Center conducted a Phase 2 clinical trial in which PET evaluated “the effect of LDN on transferred lesions of breast cancer not responding to hormonal therapy” in collaboration with the National Cancer Institute.
Conclusion
Cancer treatment with low-dose naltrexone (LDN) therapy is not a treatment method to kill cancer cells such as high-concentration vitamin C infusion therapy or chemotherapeutic agent, but a treatment method to control cancer cell growth, cell division and apoptosis. It can thus be used in conjunction with conventional cancer treatment and concentrated vitamin C infusions.
Treatment process
Take 1 capsule (3 to 4.5 mg) once a day.
Treatment provided by our hospital is not covered by public insurance (free initial examination).
